Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (NASDAQ: PSTV) generates a steady flow of news as a clinical-stage pharmaceutical and healthcare company focused on targeted radiotherapeutics and precision diagnostics for central nervous system (CNS) cancers. Headquartered in Houston, Texas, the company regularly reports on its clinical trial progress, regulatory interactions, capital markets activity, and expansion of its CNSide Diagnostics subsidiary.
News about Plus Therapeutics often highlights developments related to REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational radiotherapy for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. Updates include clinical data presentations at major oncology meetings, safety and efficacy findings from the ReSPECT-GBM and ReSPECT-LM trials, and discussions with the U.S. Food and Drug Administration (FDA) on pivotal trial design and potential accelerated approval pathways.
Another key news theme is the company’s CNSide Diagnostics, LLC subsidiary and the CNSide® CSF Assay Platform. Press releases describe new state laboratory licenses, national coverage agreements with major payors, and real-world utilization metrics for the CNSide cerebrospinal fluid Tumor Cell Enumeration test used in managing leptomeningeal metastases.
Investors following PSTV can also expect announcements on financing and listing matters, such as public offerings of common stock and warrants, purchase agreements with institutional investors, and updates on Nasdaq listing compliance related to minimum bid price and equity standards. Corporate governance items, including proxy statements and stockholder meeting results, appear in both news and SEC filings.
This news page aggregates these updates so readers can track Plus Therapeutics’ clinical milestones, diagnostic platform expansion, regulatory communications, and capital markets events in one place. For those researching PSTV, it provides context on how the company is advancing its CNS cancer programs and managing its public company obligations over time.
Plus Therapeutics (PSTV) announced the first patient dosing in the ReSPECT-LM Phase 1/2a trial of 186RNL for leptomeningeal metastases, highlighting a significant step in its drug development efforts. The company reported a cash balance of $21.2 million as of March 31, 2022, reflecting an increase from $18.4 million at year-end 2021. However, total operating expenses rose to $3.9 million, leading to a net loss of $4.1 million, or $(0.19) per share, for Q1 2022. Plus Therapeutics also expanded its partnership with Medidata to enhance trial efficiency, aiming for FDA approval for multiple upcoming trials.
Plus Therapeutics (PSTV) announced an oral presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting, scheduled for June 11-14, 2022, in Vancouver, Canada. The presentation will cover new data on Rhenium-186-NanoLiposome (186RNL) for treating relapse/recurrent glioblastoma (rGBM). The presentation will be available on the company's website post-event. Plus Therapeutics is focused on developing innovative cancer treatments utilizing a proprietary nanotechnology platform to enhance drug delivery and efficacy.
Plus Therapeutics (PSTV) will announce its Q1 2022 financial results on April 21, 2022, after market close. Following the release, the management team will host a conference call at 5:00 p.m. ET to discuss the results and provide updates on the company's progress. Investors can access the live broadcast and later replay via the Plus Therapeutics website. The company focuses on developing innovative, targeted radiotherapeutics for challenging cancer types, utilizing a proprietary nanotechnology platform for drug delivery and enhancement.
Plus Therapeutics (Nasdaq: PSTV) announced its participation at the AACR 2022 Annual Meeting, presenting a poster on a biology-based model predicting recurrent glioblastoma response to treatment with 186Re-labeled nanoliposomes. The poster will be showcased on April 12, 2022, from 9:00 a.m. to 12:30 p.m. CT at the New Orleans Convention Center. Plus Therapeutics focuses on innovative cancer therapies using advanced nanotechnology for drug delivery. The company is committed to developing effective treatments for patients with difficult-to-treat cancers.
Plus Therapeutics (PSTV) announced an expanded partnership with Medidata to enhance its upcoming Phase 2 trial of Rhenium-186 NanoLiposome (186RNL) for recurrent glioblastoma. This collaboration aims to speed enrollment and reduce trial costs by utilizing Medidata's Synthetic Control Arm® platform, which incorporates historical clinical trial data, increasing patient access to innovative therapies. Dr. Norman LaFrance emphasized that this approach minimizes patient exposure to ineffective treatments. The partnership follows a successful feasibility phase, enhancing the trial's scientific validity.
Plus Therapeutics, Inc. (Nasdaq: PSTV) has announced that CEO Marc Hedrick will present at the 2022 Virtual Growth Conference from March 28-30, 2022. The conference will feature pre-recorded presentations available on-demand. Plus Therapeutics is focused on developing targeted radiotherapeutics for difficult-to-treat cancers, notably using Rhenium-186 NanoLiposome in clinical trials for recurrent glioblastoma. For more details, visit PlusTherapeutics.com.
Plus Therapeutics (PSTV) announced the initiation of the ReSPECT-LM Phase 1/2a clinical trial for Rhenium-186 NanoLiposome (186RNL), targeting leptomeningeal metastases (LM). The first patient has been dosed in this multicenter study, which evaluates safety, tolerability, and maximum tolerated/dose feasible doses of 186RNL. This treatment aims to address the unmet medical need for LM patients, who face poor survival rates and lack FDA-approved options. The FDA has granted Fast Track designation for 186RNL, allowing for expedited development and review.
Plus Therapeutics (Nasdaq: PSTV) is set to sponsor and present an industry satellite symposium titled Radiolabeled NanoLiposomes: A Novel Targeted Treatment for Rare and Central Nervous System Cancers at the Society of Nuclear Medicine and Molecular Imaging Therapeutics Conference from March 10-12, 2022, in New Orleans. The presentation will take place on March 12 at 7:15 a.m. CT, led by Chief Medical Officer Norman LaFrance. Plus Therapeutics focuses on developing radiotherapeutics, including its lead candidate, Rhenium-186 NanoLiposome, targeting recurrent glioblastoma.
Plus Therapeutics (PSTV) reported financial results for Q4 and full year 2021, showing a net loss of $13.4 million, or $(1.11) per share, compared to $8.2 million, or $(1.86) per share, in 2020. The company raised $28.5 million to strengthen its balance sheet, with cash balances at $23 million as of January 31, 2022. Notable advancements include positive interim data from the ReSPECT-GBM Phase 1/2 trial of 186RNL, plans for a Phase 2 trial in 2022, and FDA Fast Track designation for 186RNL in treating leptomeningeal metastases.
Plus Therapeutics (PSTV) announced a partnership with Medidata to evaluate the Synthetic Control Arm (SCA) in a planned Phase 2 trial for Rhenium-186 NanoLiposome (186RNL) targeting recurrent glioblastoma. SCAs may improve patient enrollment and retention by using historical data to create control groups, thereby potentially lowering trial costs while maintaining scientific integrity. The FDA has recognized a Phase 3 trial design using synthetic controls, indicating a positive regulatory outlook for innovative trial methodologies.